logo
Lebanon County to receive another round of opioid settlement funds. How it will be used.

Lebanon County to receive another round of opioid settlement funds. How it will be used.

Yahoo25-02-2025
Lebanon County is expected to receive more than $3.6 million from a second wave of opioid settlement funds, which officials want to use to create two new programs to proactively stem the opioid epidemic in the county.
Officials said this funding will be distributed over a 13-year period. The funds are from a second wave of national lawsuit settlements accusing drug manufacturers Teva and Allergan, along with pharmacy chains including CVS, Walgreens and Walmart, of contributing to the opioid addiction epidemic and related overdose deaths.
Lebanon County received its first payment of this second wave funds in 2024, according to the county Commission on Drug and Alcohol Abuse Director James Donmoyer Jr. The last payment will be in 2037.
"We're trying to keep people out of jail and in treatment," Donmoyer said to county commissioners Feb. 19 about the programs funded by opioid settlement funds. "They're in jail, they are not real productive to anyone honestly."
This second wave of funds is in an addition to the more than $4.178 million the county received in 2022 for opioid settlement funding. The first wave was part of a settlement in 2022 with pharma distributors that included Cardinal Health, McKesson and AmerisourceBergen, along with manufacturer Johnson & Johnson.
The bulk of these new funds will be put towards a medication assistant treatment, also known as MAT, induction program at Lebanon County Correctional Facility costing $150,000 a year. The total cost of the program will be $1.95 million over 13 years.
County commissioners originally approved a MAT maintenance program for the correctional facility in 2022 costing $100,000 a year with the first wave of opioid settlement funds. The total cost of the program will be $1.8 million by 2037, when the first wave of funds also run out.
"Induction simply means someone comes into the prison, they are not on any MAT but they wish to start MAT," Donmoyer said. "So not only are we going to be able to maintain someone on MAT while in the county prison, but we'll also be able to start them while their in the county prison."
Both programs will be facilitated through PrimeCare Medical, which provides comprehensive health care services for the correctional facility.
The Lebanon County Correctional Facility has an average daily population of around 300 inmates. Officials said the facility on average intakes about 120 new inmates a month, 8% to 12% of which require detoxification of opioids and other illegal drugs.
More than 437 patients were seen at the correctional facility for MAT maintenance for 2024, according to Donmoyer.
"We're seeing a lot of people coming into the prison on some kind of MAT want to continue, and if we don't have the programs in place for that to happen, we are going to be liable," he said.
Donmoyer added that organizations filled lawsuits against Alleghany and Delaware counties for not having similar programs.
Officials used the first wave of settlement funds to hire a dedicated adult parole officer to manage opiate addicts at $90,000 a year. Donmoyer said they currently have a caseload of 35 individuals as of January, and 25 are in treatment.
In a 2-to-1 vote Feb. 20, Lebanon County Commissioners approved using the settlement funds for MAT induction program. Commissioner Jo Ellen Litz vote no, requesting the county put facilitating the program out for bid.
County officials also put $25,000 per year of second wave funds towards an opioid use disorder outreach workers program with the Recovery Advocacy Service Empowerment, or RASE, Project. The total cost of the program will be $325,000 over the next 13 years.
Donmoyer said it will be an "on the ground" type of service, acting as a referral per person to get residents' needs addressed, including drug and alcohol services.
"It's basically outreach workers going into our community and addressing this population on a lot of major fronts as far as health, transportation, education, homelessness," Donmoyer said. "They help refer these individuals to the services they need in our community."
The service was originally provided by Alder Health before the COVID pandemic. Donmoyer said RASE would be providing the service one day a week through Lebanon County.
Matthew Toth is a reporter for the Lebanon Daily News. Reach him at mtoth@ldnews.com or on Twitter at @DAMattToth.
This article originally appeared on Lebanon Daily News: Lebanon County pro-active with new round of opioid settlement funding
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Stock Movers: Novo Nordisk, GoodRX, CVS
Stock Movers: Novo Nordisk, GoodRX, CVS

Bloomberg

timea day ago

  • Bloomberg

Stock Movers: Novo Nordisk, GoodRX, CVS

On this episode of Stock Movers: - Novo Nordisk (NVO) shares rise after news that it's slashing the cost of Ozempic for cash-paying patients to $499 a month through NovoCare and partnering with GoodRx Holdings Inc. to offer it at the same price at US pharmacies. - GoodRX (GDRX) shares surge on news Novo Nordisk is slashing the cost of Ozempic and partnering with GoodRx to offer it at US pharmacies. - CVS (CVS) shares gain after UBS upgraded the drugstore chain to buy from neutral. Analyst Kevin Caliendo writes that the upgrade follows 'two strong consecutive quarters of execution and early signs that the Healthcare Benefits (HCB) segment fixes are on track.'

UBS upgrades CVS, says turnaround in health benefits business gaining traction
UBS upgrades CVS, says turnaround in health benefits business gaining traction

Yahoo

time2 days ago

  • Yahoo

UBS upgrades CVS, says turnaround in health benefits business gaining traction

-- UBS upgraded CVS Health (NYSE:CVS) to Buy from Neutral and raised its price target to $79, saying recent cost controls and execution in the company's healthcare benefits arm are beginning to show results and the improvement is not yet priced into the stock. The brokerage said CVS has posted two consecutive quarters of stronger-than-expected results, helped by better forecasting of Medicare Advantage utilization and early signs that fixes to its underperforming group insurance segment are working. UBS now expects CVS earnings to grow at a 14% compound annual rate through 2028, above its previous forecast and the Street's estimated 12%. Analysts pointed to CVS correctly cutting benefits and recalibrating assumptions in its Medicare Advantage plans for this year, leading to a more stable claims trend and meaningful reserve release. They estimate the group Medicare Advantage business, where roughly half of contracts are being repriced in 2025, could move from negative mid-to-high single-digit margins to positive territory, contributing an estimated $0.46 per share in 2026 earnings. UBS also expects CVS to return to roughly 3.5x leverage by late 2026, creating room for share buybacks and further earnings growth. At around nine times 2026 earnings, the stock trades below its long-term historical average of 10 times, despite a reaccelerating growth profile. Risks include potential deterioration in Medicare Star quality ratings in October, and pending U.S. regulation on drug pricing or pharmacy-benefit managers. But UBS said CVS remains confident in its Stars positioning, noting that about 65% of plan members are in contracts rated 4.5 stars or higher well above the bonus threshold. Related articles UBS upgrades CVS, says turnaround in health benefits business gaining traction Bernstein upgrades Toyota stock as journey to 20% RoE kicks off AI could deliver $920B in annual net benefits to S&P 500 firms Sign in to access your portfolio

CVS Health Corporation (CVS) Is 'The Last Man Standing,' Says Jim Cramer
CVS Health Corporation (CVS) Is 'The Last Man Standing,' Says Jim Cramer

Yahoo

time2 days ago

  • Yahoo

CVS Health Corporation (CVS) Is 'The Last Man Standing,' Says Jim Cramer

We recently published . CVS Health Corporation (NYSE:CVS) is one of the stocks Jim Cramer recently discussed. CVS Health Corporation (NYSE:CVS) is a pharmaceutical retailer whose shares are among the top performers in the industry. They have gained 55% year-to-date and are up by 16.8% since late July. CVS Health Corporation (NYSE:CVS) has performed well on the stock market as its rivals continue to struggle. In his previous remarks about the firm, Cramer has commented on the competitive dynamics and speculated that the stock could go even higher. Here are his latest comments about CVS Health Corporation (NYSE:CVS): '[On a Baird upgrade] I think that they are the last man standing, with Rite Aid pulling back and Walgreen, they're shutting a huge amount of Walgreen since they were sold. I think that by the way, David Joiner, non-promotional. Did a remarkable job in terms of health insurance. They are the one to bet on if you want to be in that area. I don't want to be in that area after reading Semblest let's just put a gun to my head with five bullets I don't want to go there, just bad ratio.' Previously, Cramer discussed CVS Health Corporation (NYSE:CVS)'s stock price: 'Right, and remember, Walgreens shrinkings, Rite-Aid gone away, 185 million people now go to these, including 60 million people who use two or more of their offerings. David, I've got to tell you, they are, if you remember, the one that was the worst, they're now the first. David Joiner, congratulations, you know how to price your business. And, they're getting out of the individual exchange plans in 2026. Goodbye Medicaid? 'Guidance goes, six, six twenty, from five seventy five, six dollars, there's a stock that going to . . .one hundred dollars!' While we acknowledge the potential of CVS as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the . READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store